ValuEngine cut shares of Aytu Bioscience (NASDAQ:AYTU) from a buy rating to a hold rating in a report published on Tuesday, December 24th, ValuEngine reports.

Several other research firms have also recently commented on AYTU. Northland Securities started coverage on shares of Aytu Bioscience in a report on Friday, November 15th. They set a buy rating and a $5.00 price target on the stock. Zacks Investment Research lowered Aytu Bioscience from a hold rating to a sell rating in a report on Tuesday, December 17th. Finally, LADENBURG THALM/SH SH boosted their target price on Aytu Bioscience from $4.00 to $4.75 in a research note on Wednesday, September 18th.

NASDAQ AYTU traded down $0.05 during trading on Tuesday, reaching $0.85. 69,438 shares of the companys stock were exchanged, compared to its average volume of 99,631. The firm has a market capitalization of $18.59 million, a PE ratio of -0.24 and a beta of 4.61. Aytu Bioscience has a fifty-two week low of $0.65 and a fifty-two week high of $2.61. The companys fifty day simple moving average is $0.86 and its 200-day simple moving average is $1.25.

Aytu Bioscience (NASDAQ:AYTU) last posted its quarterly earnings results on Thursday, November 14th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.02). Aytu Bioscience had a negative return on equity of 252.42% and a negative net margin of 390.43%. The company had revenue of $1.44 million for the quarter, compared to analyst estimates of $1.45 million. As a group, sell-side analysts expect that Aytu Bioscience will post -1.3 earnings per share for the current fiscal year.

In other Aytu Bioscience news, CEO Joshua R. Disbrow bought 55,000 shares of the stock in a transaction on Thursday, December 19th. The shares were purchased at an average cost of $0.83 per share, with a total value of $45,650.00. Also, major shareholder Armistice Capital Master Fund bought 78,788 shares of the businesss stock in a transaction on Friday, December 20th. The shares were bought at an average price of $0.90 per share, for a total transaction of $70,909.20. Insiders own 5.80% of the companys stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Aytu Bioscience during the 2nd quarter valued at about $36,000. Virtu Financial LLC acquired a new stake in Aytu Bioscience in the 3rd quarter worth approximately $36,000. Bank of New York Mellon Corp acquired a new stake in Aytu Bioscience in the 2nd quarter worth approximately $75,000. Finally, Searle & CO. boosted its position in Aytu Bioscience by 24.1% during the third quarter. Searle & CO. now owns 249,848 shares of the companys stock worth $302,000 after purchasing an additional 48,601 shares during the period. Institutional investors own 27.76% of the companys stock.

Aytu Bioscience Company Profile

Aytu BioScience, Inc, a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia.

See Also: How is the LIBOR rate calculated?

To view ValuEngines full report, visit ValuEngines official website.

Receive News & Ratings for Aytu Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

The rest is here:
Aytu Bioscience (NASDAQ:AYTU) Stock Rating Lowered by ValuEngine - Riverton Roll

Comments are closed.